Cellares, a cell therapy manufacturing specialist, announced layoffs of 100 employees after an unnamed large pharmaceutical customer terminated a contract. The company characterized the restructuring as driven by loss of the customer agreement, pointing to the fragility of manufacturing-services demand when client relationships change. For CDMOs and cell-therapy service providers, contract terminations can quickly affect utilization rates, staffing plans, and the ability to fund capacity expansion. Investors and partners may view the move as a near-term operational stress test for the cell therapy supply chain. The announcement also highlights that manufacturing execution risks remain commercial as well as technical—particularly for platform-scale providers navigating variable downstream customer schedules. The episode may influence how sponsors evaluate redundancy, contract clauses, and production forecasting when selecting partners for gene and cell therapy manufacturing.